AR074678A1 - Metodos y composiciones basados en pcv2 (circovirus porcino de tipo 2) para el tratamiento de cerdos - Google Patents

Metodos y composiciones basados en pcv2 (circovirus porcino de tipo 2) para el tratamiento de cerdos

Info

Publication number
AR074678A1
AR074678A1 ARP090104893A ARP090104893A AR074678A1 AR 074678 A1 AR074678 A1 AR 074678A1 AR P090104893 A ARP090104893 A AR P090104893A AR P090104893 A ARP090104893 A AR P090104893A AR 074678 A1 AR074678 A1 AR 074678A1
Authority
AR
Argentina
Prior art keywords
pcv2 orf2
pcv2
modified
nucleic acid
orf2
Prior art date
Application number
ARP090104893A
Other languages
English (en)
Inventor
Michael G Sheppard
Sui T Lay
Original Assignee
Vectogen Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vectogen Pty Ltd filed Critical Vectogen Pty Ltd
Publication of AR074678A1 publication Critical patent/AR074678A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/10011—Circoviridae
    • C12N2750/10032—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/10011—Circoviridae
    • C12N2750/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Plant Pathology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Métodos y composiciones para vacunar cerdos contra enfermedades asociadas con circovirus porcinos. Reivindicación 1: Un vector de expresión recombinante caracterizado porque comprende una secuencia de ácido nucleico, que codifica un ORF2 de PCV2 modificado, unido operativamente a un promotor, donde: a) el ORF2 de PCV2 modificado es uno donde se ha modificado o eliminado la senal de localización nuclear del ORF2 de PCV2 tipo salvaje para permitir la secreción de la proteína del ORF2 truncada al realizarse la expresión; o b) el ORF2 de PCV2 modificado es uno donde se ha eliminado la senal de localización nuclear y se la ha reemplazado por una secuencia senal hidrofóbica que dirige la expresión del ORF2 de PCV2 sobre la superficie de la célula infectada. Reivindicación 20: Una vacuna para la protección de cerdos de un trastorno asociado con PCV2, caracterizada porque dicha vacuna comprende un vector basado en el adenovirus recombinante porcino 3, que comprende un promotor unido operativamente a una secuencia senal hidrofóbica, que comprende un ácido nucleico que codifica un dominio de anclaje a la membrana y un ácido nucleico que codifica un ORF2 de PCV2 truncado que carece de una secuencia NLS, insertado en el mismo marco con dicha secuencia senal hidrofóbica, una senal de poliadenilación y un genoma del adenovirus porcino 3.
ARP090104893A 2008-12-15 2009-12-15 Metodos y composiciones basados en pcv2 (circovirus porcino de tipo 2) para el tratamiento de cerdos AR074678A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US12255508P 2008-12-15 2008-12-15

Publications (1)

Publication Number Publication Date
AR074678A1 true AR074678A1 (es) 2011-02-02

Family

ID=42240826

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP090104893A AR074678A1 (es) 2008-12-15 2009-12-15 Metodos y composiciones basados en pcv2 (circovirus porcino de tipo 2) para el tratamiento de cerdos

Country Status (14)

Country Link
US (1) US20100150959A1 (es)
EP (1) EP2376639A1 (es)
JP (1) JP2012511896A (es)
KR (1) KR20110123725A (es)
CN (1) CN102333876A (es)
AR (1) AR074678A1 (es)
AU (1) AU2009328622A1 (es)
BR (1) BRPI0923514A2 (es)
CA (1) CA2746340A1 (es)
EA (1) EA201170813A1 (es)
MX (1) MX2011006400A (es)
SG (1) SG172183A1 (es)
TW (1) TW201026850A (es)
WO (1) WO2010068969A1 (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA95602C2 (ru) 2004-12-30 2011-08-25 Берингер Ингельхейм Ветмедика, Инк. Иммуногенная композиция цвс2 и способы приготовления такой композиции
ES2572736T3 (es) 2005-12-29 2016-06-02 Boehringer Ingelheim Vetmedica, Inc. Uso de una composición inmunógena para atenuar síntomas clínicos en cerdos
CN102698263B (zh) 2005-12-29 2016-07-06 贝林格尔.英格海姆维特梅迪卡有限公司 多价pcv2免疫原性组合物和制备此类组合物的方法
EP2101815A4 (en) 2006-12-11 2010-10-06 Boehringer Ingelheim Vetmed EFFICIENT PROCESS FOR THE TREATMENT OF PORCINE CIRCOVIRUS AND LAWSONIA INTRACELLULARIS INFECTIONS
EP1941903A1 (en) 2007-01-03 2008-07-09 Boehringer Ingelheim Vetmedica Gmbh Prophylaxis and treatment of PRDC
EP1958644A1 (en) 2007-02-13 2008-08-20 Boehringer Ingelheim Vetmedica Gmbh Prevention and treatment of sub-clinical pcvd
CN101884787A (zh) * 2010-07-22 2010-11-17 洛阳普莱柯生物工程有限公司 猪圆环病毒2型亚单位疫苗及其制备方法
CN102827289B (zh) * 2012-08-30 2014-04-09 青岛蔚蓝生物股份有限公司 猪圆环病毒2型Cap蛋白和胸腺素α1融合蛋白及应用
CN102824634B (zh) * 2012-09-14 2014-03-19 范红结 表达猪圆环病毒2型Cap蛋白的重组猪痘病毒载体疫苗及其制备方法
CN103920146A (zh) * 2013-01-14 2014-07-16 普莱柯生物工程股份有限公司 猪圆环病毒ⅱ型与猪伪狂犬病二联疫苗及其制备方法和应用
EP2789346A1 (en) * 2013-04-11 2014-10-15 CEVA Santé Animale SA Fusion polypeptides and vaccines
US20140348874A1 (en) * 2013-05-22 2014-11-27 Boehringer Ingelheim Espana, S.A. Method for the reduction of pcv-2 in a herd of swine
CN104031925A (zh) * 2014-02-24 2014-09-10 福州大北农生物技术有限公司 优化的猪圆环病毒orf2基因的nls序列
CN104017813A (zh) * 2014-06-03 2014-09-03 斯澳生物科技（苏州）有限公司 截短的pcv2型衣壳蛋白orf2病毒样颗粒及其制备方法
KR102055215B1 (ko) * 2015-12-28 2020-01-22 애그리컬쳐럴 테크놀로지 리서치 인스티튜트 돼지 써코바이러스 2형 캡시드 단백질 및 이를 포함하는 약학적 조성물의 제조 방법
EP3254692A1 (en) 2016-06-10 2017-12-13 Ceva Sante Animale Multivalent recombinant spv
CN106399350B (zh) * 2016-09-07 2020-02-21 复旦大学 一种猪圆环病毒ii型病毒样颗粒疫苗及其制备方法
KR102480771B1 (ko) 2017-10-17 2022-12-23 인터벳 인터내셔널 비.브이. 곤충 세포에서의 pcv2b orf2 단백질의 재조합 발현
GB2574609A (en) * 2018-06-11 2019-12-18 Univ Cape Town Plant produced porcine circovirus pseudovirion
PE20211141A1 (es) * 2019-12-19 2021-06-25 Farm Veterinarios S A C Salmonella enteritidis recombinante y su uso como vacuna porcina
CN112834744A (zh) * 2020-12-31 2021-05-25 天津瑞普生物技术股份有限公司 一种猪群体内腺病毒3型中和抗体阳性率的elisa试剂盒及其检测方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5831023A (en) * 1982-11-01 1998-11-03 Genentech, Inc. Recombinant animal interferon polypeptides
US5151267A (en) * 1988-07-15 1992-09-29 University Of Saskatchewan Bovine herpesvirus type 1 polypeptides and vaccines
AUPO856097A0 (en) * 1997-08-14 1997-09-04 Commonwealth Scientific And Industrial Research Organisation Vector
FR2772047B1 (fr) * 1997-12-05 2004-04-09 Ct Nat D Etudes Veterinaires E Sequence genomique et polypeptides de circovirus associe a la maladie de l'amaigrissement du porcelet (map), applications au diagnostic et a la prevention et/ou au traitement de l'infection
FR2789695B1 (fr) * 1999-02-11 2003-03-07 Merial Sas Vecteurs et vaccins viraux a base d'adenovirus porcins recombines et replicatifs
US6852705B2 (en) * 2000-01-21 2005-02-08 Merial DNA vaccines for farm animals, in particular bovines and porcines
CN1769434A (zh) * 2005-08-30 2006-05-10 广东省农业科学院兽医研究所 一种猪圆环病毒2型重组腺病毒及其构建方法和应用
KR20090038910A (ko) * 2006-07-28 2009-04-21 커먼웰쓰 사이언티픽 앤드 인더스트리얼 리서치 오가니제이션 재조합 아데노바이러스 벡터의 조직 향성을 증가시키기 위한 방법 및 조성물
CN101092631B (zh) * 2007-05-31 2010-04-14 华中农业大学 一种修饰的猪圆环病毒2型orf2基因及应用

Also Published As

Publication number Publication date
US20100150959A1 (en) 2010-06-17
EP2376639A1 (en) 2011-10-19
EA201170813A1 (ru) 2012-01-30
CN102333876A (zh) 2012-01-25
BRPI0923514A2 (pt) 2019-08-20
TW201026850A (en) 2010-07-16
JP2012511896A (ja) 2012-05-31
AU2009328622A1 (en) 2011-07-07
WO2010068969A1 (en) 2010-06-24
MX2011006400A (es) 2011-09-15
KR20110123725A (ko) 2011-11-15
SG172183A1 (en) 2011-07-28
CA2746340A1 (en) 2010-06-24

Similar Documents

Publication Publication Date Title
AR074678A1 (es) Metodos y composiciones basados en pcv2 (circovirus porcino de tipo 2) para el tratamiento de cerdos
CO6290791A2 (es) Vacunas y composiciones inmunogénicas que contienen nuevas cepas del circo virus porcino tipo 2b para inmunizar cerdos contra pmws
EA201170812A1 (ru) Способы и композиции для применения вакцины против кокцидиоза
Beach et al. Efficacy and future prospects of commercially available and experimental vaccines against porcine circovirus type 2 (PCV2)
CL2019002280A1 (es) Vectores virales, adenovirales y composiciones a base de una secuencia de ornitina transcarbamilasa humana (hotch) modificada genéticamente y su uso en el tratamiento de deficiencia de la otc. (divisional solicitud 201602235)
AR102006A1 (es) Vacunas recombinantes contra el virus de la fiebre aftosa (fmdv) y sus usos
BR112012023234A2 (pt) vacina de circovírus vivo atenuado quimérico porcino
GB0712160D0 (en) Methods and compositions in the treatment of procine circoviral infection
BR112012023046A2 (pt) vacinas de vírus de febre aftosa recombinantes e seus respectivos usos
AR080313A1 (es) Composiciones de virus de moquillo canino (cdv) recombinante y sus usos
WO2013036791A3 (en) Modified adenoviral vectors and methods of treatment using same
BR112012021650A2 (pt) "parvovírus recombinante atenuado, vacina para a proteção de animais contra infecção com parvovírus, método para a obtenção de um parvovírus recombinante, e, uso de uma vacina."
CL2012000447A1 (es) Composición o vacuna que comprende un vector viral de un paramixovirus aviar 8 (apmv-8) recombinante; método para producir dicho vector; y uso para preparar medicamento útil para inducir una respuesta inmunológica.
BR112015025898A2 (pt) polipeptídeo, célula, ácido nucleico, vetor, vírus da varíola suína recombinante, composição, vacina, e uso de um peptídeo sinal
CO6440541A2 (es) Virus de diarrea viral bovina con una proteina erns modificada
ES2525358T3 (es) Uso de parvovirus para eliminar células madre cancerígenas (CSC)
BRPI0816134A2 (pt) Herpesvírus, sequência de dna, vetor, célula, vírus, método para produção de partículas infecciosas, partículas infecciosas, vacina, uso de herpesvírus ou da sequência de dna ou do vetor ou das partículas infecciosas, e, método para o tratamento preventivo e/ou terapêutico de uma doença.
CN109863169A (zh) 具有连接至不变链(cd74)的短片段的抗原的融合肽
CL2013001877A1 (es) Composicion inmunogenica que comprende un virus de diarrea viral bovina tipo 1b vivo modificado y un portador veterinario aceptable; vacuna que la comprende; y su uso para prevenir, tratar, manejar o aliviar uno o mas sintomas de una enfermedad causada por pestivirus.
BR112014001409A2 (pt) métodos e composições para vacinação contra staphylococcus aureus
CO7461133A2 (es) Parvovirus 5a porcino, métodos de uso y vacuna
BRPI0920622A8 (pt) vacina contra o vírus da doença equina africana
NI201700080A (es) Composiciones de vacuna para el virus del dengue y métodos de uso de las mismas.
WO2012036391A3 (ko) 돼지 써코바이러스２(ｐｃｖ２) 유전자의 표면발현용 벡터 및 이로 형질전환된 살모넬라 백신 균주
BR112019008720A2 (pt) polinucleotídeo isolado, polinucleotídeo de cdna, polinucleotídeo infeccioso, composição, composição farmacêutica, vetor de pestivírus porcino, pestivírus quimérico, vacina para animais, kit, métodos para proteger um leitão contra uma doença associada com pestivírus, detectar pestivírus, detectar antígeno de pestivírus, preparar uma vacina e controlar uma infecção com um pestivírus em animais, e, ensaio diagnóstico

Legal Events

Date Code Title Description
FB Suspension of granting procedure